Figure 1.

Frequency of ocular inflammatory attacks and fluorescein vascular leakage scores before and after initiation of infliximab therapy. (a) The number of ocular inflammatory attacks before and after initiation of infliximab treatment was converted to frequency/year. The mean±SE for all patients is shown for each time point. Statistical analysis was performed using the Wilcoxon signed-rank test. *P<0.05 versus baseline. (b) Frequency of ocular attacks/year for individual patient over each 1-year period. (c) To assess degree of vascular leakage, FA was performed at times of clinical quiescence before the initiation of infliximab therapy (baseline) and at the end of years 1, 2, 3, and 4 on infliximab. Degree of fluorescein leakage was graded on a scale of 0–3 (0=none, 1=mild, 2=moderate, 3=severe) for the optic disc, the macula, and the peripheral retina of each study eye by two masked graders, and averaged. The total vascular leakage score represents the sum of the averages for the disc, macula and peripheral retina. The mean±SE for all patients is shown at each time point. Statistical analysis was performed using the Wilcoxon signed-rank test. *P<0.05 versus baseline. (d) Total vascular leakage scores are shown for individual patients at baseline and at the end of years 1, 2, 3, and 4 on infliximab. M=months.